9 completed. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 3 | Completed 3 |
Follow Glycotope GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab) - Solid Tumor, Adult | Phase 1 | Completed | Glycotope GmbH | 50 | 2017-11-02 | 2021-07-12 |
| CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer CetuGEX™, Cetuximab, Chemotherapy - Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Completed | Glycotope GmbH | 240 | 2014-02-01 | 2021-11-02 |
| PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer PankoMab-GEX, Placebo - Ovarian Epithelial Cancer Recurrent, Fallopian Tube Cancer | Phase 2 | Completed | Glycotope GmbH | 216 | 2013-09-01 | 2020-10-22 |
| Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f® Follitropin Epsilon, Follitropin Alfa - Infertility | Phase 2 | Completed | Glycotope GmbH | 267 | 2013-01-08 | 2021-05-07 |
| Multiple Dose FSH-GEX(TM) in Healthy Volunteers FSH-GEX™, recombinant FSH, urinary FSH - Female Infertility | Phase 1 | Completed | Glycotope GmbH | 57 | 2011-10-01 | 2021-05-07 |
| TrasGEX™: Phase 1 Study in Cancer Patients TrasGEX™ - Solid Tumors | Phase 1 | Completed | Glycotope GmbH | 37 | 2011-07-01 | 2021-05-07 |
| Single Dose FSH-GEX™ in Healthy Volunteers FSH-GEX™, Gonal-f, Bravelle - Female Infertility | Phase 1 | Completed | Glycotope GmbH | 19 | 2011-04-01 | 2021-05-11 |
| CetuGEX™: Phase 1 Study in Cancer Patients CetuGEX™ - Solid Tumors | Phase 1 | Completed | Glycotope GmbH | 41 | 2010-08-01 | 2021-05-25 |
| PankoMab-GEX™: Phase 1 Dose Escalation Study PankoMab-GEX™ - Solid Tumors | Phase 1 | Completed | Glycotope GmbH | 74 | 2009-11-01 | 2021-05-20 |
Infertility, Female (2) · Fallopian Tube Neoplasms (1) · Infertility (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
PankoMab-GEX (3) · follitropin alfa (3) · Cetuximab (2) · Urofollitropin (2) · Drug Therapy (1) · Fluorouracil (1) · GAT (1) · Panitumumab (1) · necitumumab (1)
Germany (7) · Italy (6) · Spain (3) · Switzerland (3) · Hungary (2) · Netherlands (2) · Poland (2) · Romania (2) · Austria (1) · Belgium (1) · France (1) · Russia (1) · United Kingdom (1)
Jonathan Ledermann, MD (1) · Sebastian Ochsenreither, Dr. med. (1) · Ulrich Keilholz, Prof (1)
PMID 28591833, PMID 27285281, PMID 29464112, PMID 30018811, PMID 31982355, PMID 34920291, PMID 35397434
2017 (1)